Evogene Ltd.EVGNEarnings & Financial Report
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technolo...
EVGN Q2 2025 Key Financial Metrics
売上高
$3.2M
粗利益
$1.6M
営業利益
$-6.1M
純利益
$-7.7M
粗利益率
48.8%
営業利益率
-189.0%
純利益率
-237.7%
前年比成長
40.7%
資金フロー
Evogene Ltd. Q2 2025 Financial Summary
Evogene Ltd. reported revenue of $3.2M (up 40.7% YoY) for Q2 2025, with a net profit of $-7.7M (up 22.0% YoY) (-237.7% margin). Cost of goods sold was $1.7M, operating expenses totaled $7.7M.
Key Financial Metrics
| Total Revenue | $3.2M |
|---|---|
| Net Profit | $-7.7M |
| Gross Margin | 48.8% |
| Operating Margin | -189.0% |
| Report Period | Q2 2025 |
Evogene Ltd. Quarterly Revenue & Net Profit History
Evogene Ltd. quarterly results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $3.2M | +40.7% | $-7.7M | -237.7% |
| Q2 2024 | $2.3M | +77.1% | $-9.8M | -428.5% |
損益計算書
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 売上高 | $2.3M | $3.2M |
| 前年比成長 | 77.1% | 40.7% |
貸借対照表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 総資産 | $41.0M | $33.9M |
| 総負債 | $21.0M | $21.6M |
| 株主資本 | $19.9M | $12.4M |
キャッシュフロー
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 営業CF | $-9.6M | $-7.5M |